Redmile Group’s AbbVie ABBV Stock Holding History

Redmile Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,388,904	Closed	-$149M	–	87
2020 Q4	$149M	Buy	+1,388,904	New	+$133M	1.8%	16
2015 Q3	–	Sell	-510,010	Closed	-$34.3M	–	59
2015 Q2	$34.3M	Buy	+510,010	New	+$33.3M	2.81%	9

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Redmile Group's ABBV Position: Q1 2021 in Review

Redmile Group sold out of AbbVie (ABBV) in Q1 2021, closing a stake of 1,388,904 shares — an estimated $149M sold.

Redmile Group first reported a position in ABBV in Q2 2015 and held it in 2 quarters. The position peaked at $149M in Q4 2020. 2,615 funds tracked by Wall St. Rank hold ABBV as of Q1 2021.

Redmile Group reported no remaining AbbVie position as of Q1 2021 after selling out during the quarter.
Redmile Group sold 1,388,904 AbbVie shares in Q1 2021, an estimated $149M.
Redmile Group first reported a position in AbbVie in Q2 2015 and held it in 2 quarters.
Redmile Group's AbbVie position peaked at $149M in Q4 2020.
2,615 funds tracked by Wall St. Rank held AbbVie as of Q1 2021.

Based on Redmile Group's 13F filing for Q1 2021, filed 17 May 2021.